REMINDER: Jaguar Health to Host Investor Webcast Monday, September 20th at 8:30 AM Eastern Time
Click here to register for webcast
Jaguar kicks off educational awareness contest in honor of Indigenous Peoples' Day; Click here to enter
Participation Instructions for Webcast
Participant Registration & Access Link: Click Here
Jaguar Kicks Off Educational Awareness Contest in Honor of Indigenous Peoples' Day
In honor of Indigenous Peoples' Day (
The winner will receive a copy of Plants, People, and Culture: The Science of Ethnobotany, by
The winner will be chosen at random from the pool of contest participants who correctly answer all or most questions in the multiple-choice form. Entries must be received by
Stay tuned to the "
For more information about Jaguar, please visit https://jaguar.health. For more information about
Mytesi® (crofelemer delayed release tablets) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi® is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi®. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).
More information and complete Prescribing Information are available at Mytesi.com. Crofelemer, the active ingredient in Mytesi®, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity.
Certain statements in this press release constitute "forward-looking statements." These include statements regarding Jaguar's expectation that an investor webcast will take place